Blood Stream Infection Testing Market Report 2026

The blood stream infection testing market size has grown rapidly in recent years. It will grow from $8.49 billion in 2025 to $9.5 billion in 2026 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to increasing incidence of bloodstream infections, rising hospital-acquired infection rates, expansion of clinical microbiology laboratories, adoption of automated diagnostic instruments, growing awareness of sepsis management.

The blood stream infection testing market size is expected to see rapid growth in the next few years. It will grow to $14.71 billion in 2030 at a compound annual growth rate (CAGR) of 11.6%. The growth in the forecast period can be attributed to increasing demand for rapid diagnostic turnaround times, rising adoption of molecular diagnostics in hospitals, expansion of personalized infection management, growing investments in advanced laboratory infrastructure, increasing integration of ai-assisted diagnostic tools. Major trends in the forecast period include increasing adoption of rapid molecular diagnostic assays, rising use of automated blood culture systems, growing integration of antimicrobial susceptibility testing, expansion of multiplex pathogen detection panels, enhanced focus on early sepsis diagnosis.

The rising prevalence of infectious diseases is expected to drive the growth of the bloodstream infection testing market in the coming years. Infectious diseases are caused by pathogenic microorganisms, including bacteria, viruses, fungi, or parasites. Rates of infectious diseases are increasing due to factors such as greater global travel, urbanization, climate change, antibiotic resistance, and gaps in vaccination coverage. Bloodstream infection testing plays a critical role in diagnosing and identifying pathogens responsible for sepsis and other severe infections, enabling targeted and effective treatment. For example, in October 2024, the World Health Organization, a Switzerland-based international public health organization, reported that approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, up from about 7.5 million in 2022, making tuberculosis the leading infectious disease killer. Consequently, the rising prevalence of infectious diseases is propelling the growth of the bloodstream infection testing market.

Key players in the bloodstream infection testing market are focusing on advanced technologies, such as host-response diagnostics using machine learning, to improve rapid detection, clinical decision support, and patient management. Host-response diagnostics assess a patient’s immune system by analyzing gene expression signatures in blood samples with AI-driven algorithms to determine the presence, type, and likely severity of infection in real time, helping clinicians make faster and more accurate treatment decisions. For instance, in January 2025, Inflammatix Inc., a US-based molecular diagnostics company, received clearance from the US Food and Drug Administration for TriVerity, a machine-learning-based molecular blood test. TriVerity is designed to rapidly evaluate patients with suspected acute infections or sepsis by measuring 29 immune-related mRNAs and generating AI-based scores indicating the likelihood of bacterial or viral infection and the risk of severe illness, with results available in roughly 30 minutes. The test supports clinical decision-making by reducing diagnostic uncertainty, assisting timely targeted therapy, and optimizing hospital resource use when combined with standard clinical evaluation and laboratory findings.

In January 2023, Thermo Fisher Scientific Inc., a US-based life sciences and clinical research company, acquired Binding Site Group Ltd. for $2.8 billion. This acquisition is intended to expand Thermo Fisher's specialty diagnostics segment by incorporating The Binding Site's innovative technologies for the diagnosis and monitoring of multiple myeloma, thereby enhancing clinical value, accelerating patient outcomes, and supporting growth in the diagnostics market. The Binding Site Group Ltd., based in the UK, manufactures medical diagnostic products focused on detecting cancer and immune disorders.

Major companies operating in the blood stream infection testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Danaher Corporation, Siemens Healthcare Private Limited, Becton Dickinson and Company (BD), Grifols S.A., Hologic Inc., BIOMÉRIEUX SA, Bio-Rad Laboratories Inc., Bruker Corporation, Qiagen N.V., DiaSorin S.p.A., Seegene Inc., Cepheid, Meridian Bioscience Inc., Biocartis NV, T2 Biosystems Inc., Molzym GmbH & Co. KG, Curetis GmbH, Accelerate Diagnostics Inc., OpGen Inc.

North America was the largest region in the blood stream infection testing market in 2025. The regions covered in the blood stream infection testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the blood stream infection testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the bloodstream infection testing market by increasing the cost of imported molecular diagnostic instruments, reagents, consumables, and laboratory automation systems used across hospitals and diagnostic laboratories. North America and Europe are most affected due to reliance on imported high-precision diagnostic equipment, while Asia-Pacific faces cost pressure on reagent and consumable imports. These tariffs are increasing testing costs and slowing laboratory upgrades. However, they are also encouraging local manufacturing of diagnostic reagents, regional instrument assembly, and greater investment in domestic clinical diagnostics production capabilities.

The blood stream infection testing market research report is one of a series of new reports that provides blood stream infection testing market statistics, including blood stream infection testing industry global market size, regional shares, competitors with a blood stream infection testing market share, detailed blood stream infection testing market segments, market trends and opportunities, and any further data you may need to thrive in the blood stream infection testing industry. This blood stream infection testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bloodstream infection testing involves diagnostic procedures to detect and identify pathogens in the blood, including bacteria, fungi, and viruses, that cause infections. This testing generally comprises blood cultures and molecular assays to determine the specific microorganism responsible. Accurate and timely testing is essential for the effective treatment and management of sepsis and other severe infections.

The main product categories in bloodstream infection testing include instruments, reagents and consumables, and software and services. Instruments refer to the specialized devices and equipment used to detect and analyze pathogens in blood samples, facilitating precise diagnosis and infection monitoring. Bloodstream infection testing is performed on sample types such as whole blood and blood cultures, employing technologies like polymerase chain reaction (PCR), mass spectrometry, in situ hybridization, and others. The primary end users of these tests include hospitals and diagnostic centers, laboratory service providers, academic and research institutions, and other related organizations.

The blood stream infection testing market consists of revenues earned by entities by providing services such as molecular diagnostics, serological assays, rapid diagnostic tests, next-generation sequencing, and pathogen identification and sensitivity testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood stream infection testing market also includes sales of blood culture media, molecular diagnostics kits, rapid diagnostic tests, automated blood culture systems, microbial identification panels, sepsis biomarker assays, and immunoassay kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.